Good Vita / The learning library

Teduglutide

A glucagon-like peptide-2 analogue used in short bowel syndrome care.

Educational information only. No medical advice or treatment recommendations.

← Back to the full library

Approved medicines Human trials in product label Digestive health

Also discussed as: Gattex, Revestive

What it is and how it works

Teduglutide is a GLP-2 analogue acting on intestinal adaptation and absorption. GLP-2 and GLP-1 are different pathways; a similar abbreviation does not mean the compounds share the same clinical purpose or effects.

Source for the mechanism context →

A closer look at the cited evidence

Human trials in product label

This label describes the selected source below. It is not a complete ranking of the literature, a safety score, or an approval status.

Study or assessment
DailyMed — Gattex mechanism and clinical studies
Design
Controlled and follow-up clinical studies summarized in the label.
Who or what was studied
Patients with short bowel syndrome dependent on parenteral support.
What was observed
The trials examined whether patients could reduce their need for parenteral support.
Limits of interpretation
These studies do not establish a general gut-healing product or treatment for undiagnosed digestive symptoms.
Read the cited study or assessment →

What the evidence means

Clinical studies evaluate reduction of parenteral support in a specific intestinal-failure population.

Approval and regulatory context

Gattex is approved for short bowel syndrome in patients dependent on parenteral support, within the label criteria.

Safety and uncertainty

Warnings address neoplastic growth, intestinal obstruction, biliary and pancreatic disease, and fluid overload.

What remains uncertain

Improved absorption can also change exposure to other medicines. The specialized diagnosis, treatment setting, and safety monitoring cannot be omitted when discussing the clinical evidence.

These summaries are introductory and are not a complete account of the literature, adverse effects, contraindications, or interactions. Absence of a listed risk does not mean absence of risk. Different compounds, formulations, and routes cannot be treated as interchangeable.

Sources behind this overview

Read the source in its full context. Source links support the overview; they do not imply endorsement of this library by the source organization.

Start Your Assessment